Abnormal LSD1 expression can be seen in a variety of cancers, such as blood, neuronal, thyroid, prostate, lung, colorectal, pancreatic, and breast cancers, suggesting that LSD1 can be developed as a molecular target for cancer [111, 112]. This evidence concerns the gene KDM1A and breast carcinoma.